Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

被引：0

作者：

Leleu, Xavier ^{[1
,2
]}

Beksac, Meral ^{[3
]}

Chou, Takaaki ^{[4
]}

Dimopoulos, Meletios ^{[5
]}

Yoon, Sung-Soo ^{[6
]}

Prince, Henry Miles ^{[7
]}

Pour, Ludek ^{[8
]}

Shelekhova, Tatiana ^{[9
]}

Chari, Ajai ^{[10
]}

Khurana, Monica ^{[11
]}

Obreja, Mihaela ^{[11
]}

Qi, Ming ^{[12
]}

Oriol, Albert ^{[13
]}

Siegel, David ^{[14
]}

机构：

[1] Chu, Poitiers, France

[2] Inserm 1402CIC, Poitiers, France

[3] Ankara Univ, Ankara, Turkey

[4] Niigata Canc Ctr Hpt, Niigata, Japan

[5] Natl & Kapodistrian Univ Athens, Sch Med, Hematol & Med Oncol, Dept Clin Therapeut,Sch Med, Athens, Greece

[6] Seoul Natl Univ, Seoul, South Korea

[7] Peter MacCallum Canc Inst, East Melbourne, Australia

[8] Univ Hosp Brno, Brno, Czech Republic

[9] Clin Profess Pathol, Saratov, Russia

[10] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[11] Amgen Inc, Thousand Oaks, CA USA

[12] Janssen Res & Dev LLC, Spring House, PA USA

[13] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain

[14] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

MM; multiple myeloma; carfilzomib; cross-study comparison; weekly dosing; KdD;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-040

引用

页码：S288 / S288

页数：1